Publications by authors named "Maria Castella"

Claim this Profile
T
TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model.
Aina Oliver-Caldes, Joan Mañe Pujol, Anthony M Battram, Lorena Perez-Amill, Mireia Bachiller, Maria Castella

Oncoimmunology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Quantitative Approach to Potency Testing for Chimeric Antigen Receptor-Encoding Lentiviral Vectors and Autologous CAR-T Cell Products, Using Flow Cytometry.
Juan José Mata-Molanes, Leticia Alserawan, Carolina España, Carla Guijarro, Ana López-Pecino, Maria Castella

Pharmaceutics· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High specificity of engineered T cells with third generation CAR (CD28-4-1BB-CD3-ζ) based on biotin-bound monomeric streptavidin for potential tumor immunotherapy.
Jorge Gallego-Valle, Verónica Astrid Pérez-Fernández, Jesús Rosales-Magallares, Sergio Gil-Manso, María Castellá

Front Immunol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
Núria Martínez-Cibrián, Valentín Ortiz-Maldonado, Marta Español-Rego, Andrea Blázquez, Joan Cid

Br J Haematol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma.
Noelia Maldonado-Pérez, María Tristán-Manzano, Pedro Justicia-Lirio, Elena Martínez-Planes, Pilar Muñoz, María Castella

Front Immunol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Physiological lentiviral vectors for the generation of improved CAR-T cells.
María Tristán-Manzano, Noelia Maldonado-Pérez, Pedro Justicia-Lirio, Pilar Muñoz, Marina Cortijo-Gutiérrez, María Castella

Mol Ther Oncolytics· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What will (and should) be improved in CAR immunotherapy?
Europa Azucena González-Navarro, Marta Español, Natalia Egri, Maria Castellà, Hugo Calderón

Int Rev Cell Mol Biol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiological lentiviral vectors for the generation of improved CAR-T cells.
María Tristán-Manzano, Noelia Maldonado-Pérez, Pedro Justicia-Lirio, Pilar Muñoz, Marina Cortijo-Gutiérrez, María Castella

Mol Ther Oncolytics· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.
Belén Blanco, Ángel Ramírez-Fernández, Clara Bueno, Lidia Argemí-Muntadas, Patricia Fuentes

Cancer Immunol Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with the clinical outcome of patients with relapsed/refractory CD19 acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy.
Valentín Ortiz-Maldonado, Susana Rives, Marta Español-Rego, Anna Alonso-Saladrigues, Mercedes Montoro, Maria Castella

J Immunother Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial.
Maria Castella, Miguel Caballero-Baños, Valentín Ortiz-Maldonado, Europa Azucena González-Navarro, Guillermo Suñé

Front Immunol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19 Relapsed/Refractory Malignancies.
Valentín Ortíz-Maldonado, Susana Rives, Maria Castellà, Anna Alonso-Saladrigues, Daniel Benítez-Ribas

Mol Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma.
Lorena Perez-Amill, Guillermo Suñe, Asier Antoñana-Vildosola, Maria Castella, Amer Najjar

Haematologica· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.
Matteo Libero Baroni, Diego Sanchez Martinez, Francisco Gutierrez Aguera, Heleia Roca Ho, Maria Castella

J Immunother Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia.
Julio Delgado, Miguel Caballero-Baños, Valentín Ortiz-Maldonado, Maria Castellà, Laura Magnano

Hemasphere· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions.
Maria Castella, Anna Boronat, Raquel Martín-Ibáñez, Vanina Rodríguez, Guillermo Suñé

Mol Ther Methods Clin Dev· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma.
Maria Castella, Carlos Fernández de Larrea, Beatriz Martín-Antonio

Int J Mol Sci· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natural Killer Cells: Angels and Devils for Immunotherapy.
Beatriz Martín-Antonio, Guillermo Suñe, Lorena Perez-Amill, Maria Castella, Alvaro Urbano-Ispizua

Int J Mol Sci· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ubiquitination-Linked Phosphorylation of the FANCI S/TQ Cluster Contributes to Activation of the Fanconi Anemia I/D2 Complex.
Ronald S Cheung, Maria Castella, Antonio Abeyta, Philip R Gafken, Nyka Tucker

Cell Rep· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NEK8 regulates DNA damage-induced RAD51 foci formation and replication fork protection.
Antonio Abeyta, Maria Castella, Celine Jacquemont, Toshiyasu Taniguchi

Cell Cycle· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ataxia-Pancytopenia Syndrome Is Caused by Missense Mutations in SAMD9L.
Dong-Hui Chen, Jennifer E Below, Akiko Shimamura, Sioban B Keel, Mark Matsushita, Maria Castella

Am J Hum Genet· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FANCI Regulates Recruitment of the FA Core Complex at Sites of DNA Damage Independently of FANCD2.
Maria Castella, Celine Jacquemont, Elizabeth L Thompson, Jung Eun Yeo, Ronald S Cheung

PLoS Genet· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p53 is positively regulated by miR-542-3p.
Yemin Wang, Jen-Wei Huang, Maria Castella, David George Huntsman, Toshiyasu Taniguchi

Cancer Res· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the link between MORF4L1 and risk of breast cancer.
Griselda Martrat, Christopher M Maxwell, Emiko Tominaga, Montserrat Porta-de-la-Riva, Núria Bonifaci

Breast Cancer Res· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fanconi anemia protein FANCD2 inhibits TRF1 polyADP-ribosylation through tankyrase1-dependent manner.
Alex Lyakhovich, Maria Jose Ramirez, Andres Castellanos, Maria Castella, Amanda M Simons

Genome Integr· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis